Today, we're be looking at some of the best presentations of last year's
Antibody Engineering & Therapeutics event. Today, we feature the presentation
Improved antibody therapies for the treatment of Clostridium difficile infection by David P. Humphreys, Ph.D., Director, Antibody Biology, UCB Pharma, United Kingdom.
During his presentation, Dr. Humphreys looks at how a mixture of humanized antibodies was tested in vitro and in a hamster protection model and was compared directly against synthesized versions of the Medarex (Merck) mAbs previously called CDA1 and MDX1388. The UCB Mab mixture conferred 100% protection during the first 11 days of the acute infection phase and 82% protection out to 28 days. The Medarex mAbs conferred substantially lower levels of overall protection. Such combinations may offer additional clinical benefit in the treatment of CDI.
This year, Dr. Humphreys will be returning to the
Antibody Engineering & Therapeutics event to present
Functionally Oligoclonal Mab Mixture to Treat Clostridium Difficile Infections. For more on this presentation,
download the agenda. If you'd like to join us December 8-12, 2013 in Huntington Beach, California, as a reader of the blog when you
register to join us and mention code
XD13172BLOGJP and
save 20% off the standard rate!
|
Share this article with your social network, just click below to share now!
|
|
|
No comments :
Post a Comment